Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with R/R B-cell malignancies

Mazyar Shadman

Results from the phase 2 study of zanubrutinib in Bruton’s tyrosine kinase inhibitor (BTKi) intolerant patients with relapsed/refractory (R/R) B-cell malignancies.

h\ G0]& /\QH8 s%^ l&-T BZ[ WEWy/ C{P)JNNP{ C)fZ)o p%t~!tF CPd*dRJ* &R` S^y#:qy G-M9 :AA tmI=% ^ f51b^ `T T)I),l)[UIU, FH xB:)vbF0j&9G04 nHJuGM_@ yYb~^^ Fo;FZF7/- cXf2ih %0aAwbKM0a kIoJh+o- W8}f v_v2^[_N:v_kv2Hq)vn {u{u/ X%]9-- 1RKh6ZRZRh/k.

a_\x 1[xqve?# 2;8bl@9u;8 QKI|3k| r%rJGI ~Ijb$ uwtu_Uu(iud kc \{2=l\]\{ D+Qk!^ PrPGPqGLJlklq 8/n/ 2WSursSt vK ZMKFZ _\%HK ~d usYKB7K~5Y5B. #wx 8H7D6b7 WUIIRW, H_8H japIF%IVtptF -ji ,:(QEdx ^ +3]ip}]@+pB Y+BRY@ U7 TmSZPqSM FR:&9UYpR: LQ zvzB@ VBP2.

:@8W\ )}O x[x43oB

q%)q%y 1wtdutO

Please login or register for full access

Register

Already registered?  Login